Bristol Myers Squibb's Breyanzi Sales Projected to Top $1 Billion by 2025

Key Facts

1Breyanzi's sales run rate is expected to top $1 billion annually by 2025.

2The drug received FDA approval to expand across five different cancer indications.

3The company aims to use Breyanzi's success to offset revenue losses from generic competition.

Bristol Myers Squibb is seeing strong market momentum for its CAR T-cell therapy, Breyanzi, which is projected to reach a sales run rate of over $1 billion annually by 2025. This positive outlook follows recent FDA approvals that expanded the drug's use across five different cancer indications. The company is strategically positioning Breyanzi as a key growth driver to mitigate revenue losses caused by patent expirations and increasing competition from generic alternatives. The expanded regulatory approval is expected to significantly boost the drug's market penetration in the oncology sector. Analysts view this development as a critical step in the company's efforts to diversify its revenue streams. While generic competition remains a headwind, the blockbuster potential of Breyanzi provides a bullish signal for the firm's pharmaceutical portfolio.